抗CD20单克隆抗体治疗特发性膜性肾病的研究进展  

Research progress of anti-CD20 monoclonal antibodies in the treatment of idiopathic membranous nephropathy

作　　者：张婕 何伟春[1] Zhang Jie;He Weichun(Department of Nephrology,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210003,China)

机构地区：[1]南京医科大学第二附属医院肾内科,210003

出　　处：《中国医药》2021年第7期1104-1107,共4页China Medicine

基　　金：国家自然科学基金(31571169)。

摘　　要：抗CD20单克隆抗体最初被用于治疗B细胞恶性肿瘤,因其可以削减B细胞数量从而抑制自身抗体的产生而被用于治疗自身免疫性疾病。特发性膜性肾病的传统免疫抑制治疗方案有严重的不良反应,且患者复发率较高,抗磷脂酶A2受体抗体等肾源性自身抗体的发现,为干预抗原-抗体免疫复合物的形成提供了针对性措施。本文就抗CD20单克隆抗体在特发性膜性肾病中的应用展开综述。Anti-CD20 monoclonal antibodies were initially developed to treat B-cell malignancy and have subsequently been used in the treatment of the autoimmune diseases based on the rationale that the depletion of B-cell would inhibit the production of autoantibodies.Traditional immunosuppressive therapy for idiopathic membranous nephropathy(IMN)has serious adverse reactions and a high recurrence rate in patients.The discovery of nephrogenic autoantibodies such as anti-phospholipase A2 receptor antibodies provides a clear basis for targeted measures to interfere with the formation of antigen-antibody immune complex.This review focuses on the application of anti-CD20 monoclonal antibodies in IMN.

关 键 词：特发性膜性肾病 抗CD20单克隆抗体 抗磷脂酶A2受体抗体 利妥昔单抗 

分 类 号：R692[医药卫生—泌尿科学]